Gynecological cancer is a cancer that occurs only in women. It is a condition where abnormal cells are grown and spread in the female reproductive organs such as vulva, cervix, vagina, uterus, and ovaries. There are different kinds of Gynecological cancer with respect to the affected organs that consist of cervical cancer, vulvar cancer, vaginal cancer, ovarian cancer and uterine cancer. Each gynaecologic cancer has different symptoms and signs, different prevention strategies and different risk factors.
There are several factors responsible for Gynecological cancer including early start of menstruation or late start of menopause, mutations, obesity, infertility and also infection from Human Papillomavirus (HPV). There are various ways for treating Gynecological cancer including chemotherapy, other therapies, different medication and even surgeries. The Gynecological cancer treatment depends upon the stage and type of the cancer.
Request for Analysis of COVID-19 Impact on Gynecological Cancer Drugs Market –
Increasing prevalence of Gynecological cancers leads to expansion of the Gynecological cancer drugs market. As per American Cancer Society, the most usual cancer observed in the female reproductive organs is endometrium cancer, which is a type of cervical ccancer. Moreover, in 2012, around 47,130 new cases of endometrial cancer were estimated to be diagnosed with the death of around 8,010 women in the U.S. Furthermore, American Cancer Society stated that, the 8th most common cancer among women is found to be ovarian cancer and it was perceived that around 22,280 new cases of ovarian cancer was diagnosed in the U.S. in 2012.
The other factor that boosts the growth of the Gynecological cancer drugs market is a huge investment on research and development by biotechnological and pharmaceutical companies to launch new drugs to fulfil their increasing demand in the market. Moreover, some generic manufactures also aimed to patent their drugs in the generic form for such cancer treatments. For instance, in May 2017, the launch of Doxorubicin Hydrochloride Liposome injection was approved by the US Food and Drug Administration in the U.S. market. This Doxorubicin Hydrochloride Liposome was launched by an Indian company named as Dr. Reddy’s Laboratories. It is a therapeutic drug that is equivalent to generic version of Doxil, which is a chemotherapy drug used for treating certain diseases such as multiple myeloma, AIDS-related Kaposi’s sarcoma, and ovarian cancer.
Moreover, a targeted therapy drug for women named as Zejula (niraparib) was approved by US FDA in 2017. It is used for treating some kinds of peritoneal, fallopian tube, or ovarian cancers in women. It is also used after chemotherapy for women suffering from relapsed cancer. As of March 2018, American Cancer Society has invested around US$ 9.3 million that accounted around 22 grants for cervical cancer. The amount of funding value is offered to a single or group of researches investigating on an area of cancer or a specific type of a cancer. This led to the overall Gynecological cancer drugs market growth over the forecast period.
The lucrative opportunities that lead to growth of the Gynecological cancer drugs market are advent of personalized medicine approach and advancement in cancer drug research.
Request PDF Brochure Report –
The factors that are negatively affecting growth of the Gynecological cancer drugs market are adverse effects of cancer drug therapy and threat of failure in the therapy. Moreover, high cost of drug development also restrains the market growth due to financial issues.
In 2016, the value of the global Gynecological cancer drugs market was reached up to $9,269 million. The market is growing at a CAGR of 8.1% over a forcast period (2017-2023) and is expected to reach $16,107 million by 2023.
The key players operating in the Gynecological cancer drugs market are Teva Pharmaceutical Industries Ltd., Apotex Inc., Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, Novartis AG, AstraZeneca Plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, and F. Hoffmann-La Roche AG.
The manufactures and new entrants in the Gynecological cancer drugs market are mainly involved in research and development to witness significant growth. For instance, in May 2018, the completed phase III study with Apealea was announced by Oasmia Pharmaceutical AB for treatment of ovarian cancer.
On the basis of region, the Gynecological cancer drugs market is segmented into North America, Latin America, Middle East, Asia Pacific, Africa and Europe. Among these regions, North America held the dominant position in the market and is followed by Europe market in 2016. For Instance, in 2014, Center for Disease Control and Prevention reported increasing prevalence of cervical cancer in the U.S. that around 12,578 women were diagnosed with cervical cancer with the death of 4,115 women in the U.S. This propelled the increasing demand for Gynecological cancer drugs, which in turn led to the market growth in North America.
Moreover, Asia Pacific is also anticipated to witness significant growth in the Gynecological cancer drugs market due to their government initiatives of arranging Gynecological cancer awareness campaigns and their large population pool as well. For instance, in 2016, an operational framework of national screening programme was published by the Indian government for the first time in the country. The programme was held in around 100 districts of India, where people over the age of 30 were supposed to undertake mandatory screening for cervical, oral and breast cancer.
Reasons to Purchase this Report
Current and future of global Gynecological Cancer Drugs market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Gynecological Cancer Drugs Market Taxonomy:
By Therapeutic Modality:
- Targeted Therapy
- Hormonal Therapy
- Uterine Cancer
- Ovarian Cancer
- Vaginal & Vulvar Cancer
- Cervical Cancer
- North America
- Latin America
- Asia Pacific
- Middle East
Major Point Answered in Gynecological Cancer Drugs Market Research Study are:
What will be the progress rate of the Gynecological Cancer Drugs Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Gynecological Cancer Drugs Market across different regions?
Who are the major vendors dominating the Gynecological Cancer Drugs industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Gynecological Cancer Drugs Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027